Compositions and methods for inhibition of the JAK pathway

1. A method of inhibiting an activity of a JAK kinase, comprising contacting the JAK kinase with an amount of a compound effective to inhibit an activity of the JAK kinase, wherein the compound is a compound of formula I

or pharmaceutically acceptable salt thereof, wherein:

ring A is heteroaryl;

p is 0, 1, 2 or 3 when ring A is monocyclic or p is 0, 1, 2, 3, 4, or 5 when ring A is bi- or tricyclic;

q is 0,1,2 or 3;

X is selected from the group consisting of hydrogen, alkyl, substituted alkyl, hydroxy, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, cyano, halo, nitro, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkynyl, substituted cycloalkynyl;

Y is selected from the group consisting of hydrogen, alk 1 -SO 2 N(R 4 )R 5 and alk 1 -N(R 4 )SO 2 R 5 ;

W is selected from the group consisting of alk 2 -SO 2 N(R 6 )R 7 and alk 2 -N(R 6 )SO 2 R 7 ;

alk 1 and alk 2 are each independently a bond, straight or branched chain C 1-6 alkylene group, cycloalkylene or substituted cycloalkylene wherein:

if W is alk 2 -SO 2 N(R 6 )R 7 and alk 2 is a bond, then Y is alk 1 -N(R 4 )SO 2 R 5 and alk 1 is a bond;

R 1 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl and substituted cycloalkyl;

each R 2 independently is selected from the group consisting of alkyl, substituted alkyl, alkoxy, substituted alkoxy, alkynyl, alkynyloxy, amino, substituted amino, aryl, substituted aryl, aryloxy, substituted aryloxy, cyano, cycloalkyl, substituted cycloalkyl, cycloalkoxy, substituted cycloalkoxy, heteroaryl, substituted heteroaryl, heteroaryloxy, substituted heteroaryloxy, heterocyclic, substituted heterocyclic, heterocyclyloxy, substituted heterocyclyloxy, aminoacyl, aminoacyloxy, carboxyl, carboxyl ester, carbonate ester, nitro, halo and oxo;

wherein if R 2 is oxo, then the oxo substituent is attached to a nonaromatic portion of ring A; or

R 4 and one of R 2 together with the intervening atoms bound thereto form a heterocyclic or a substituted heterocyclic fused to ring A; or

R 5 and one of R 2 together with the intervening atoms bound thereto form a heterocyclic or a substituted heterocyclic fused to ring A;

Z 1 , Z 2 , and Z 3 each independently is carbon or nitrogen, wherein 0 or 1 of Z 1 , Z 2 , and Z 3 is N; and

W is not attached to Z 1 , Z 2 or Z 3 when said Z 1 , Z 2 or Z 3 is nitrogen;

each R 3 independently is selected from the group consisting of alkyl, substituted alkyl, alkoxy, substituted alkoxy, alkynyl, alkynyloxy, amino, substituted amino, aryl, substituted aryl, aryloxy, substituted aryloxy, cyano, cycloalkyl, substituted cycloalkyl, cycloalkoxy, substituted cycloalkoxy, heteroaryl, substituted heteroaryl, heteroaryloxy, substituted heteroaryloxy, heterocyclic, substituted heterocyclic, heterocyclyloxy, substituted heterocyclyloxy, aminoacyl, aminoacyloxy, carboxyl, carboxyl ester, carbonate ester, nitro, halo, and aminosulfonyl; or

R 6 and one of R 3 , together with the intervening atoms bound thereto form a heterocyclic or a substituted heterocyclic fused to the ring containing Z 1 , Z 2 and Z 3 ; or

R 7 and one of R 3 , together with the intervening atoms bound thereto form a heterocyclic or a substituted heterocyclic fused to the ring containing Z 1 , Z 2 and Z 3 ; or

R 4 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocyclic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, acyl and M + , wherein M + is a counterion selected from the group consisting of K + , Na + , Li + and + N(R 8 ) 4 , wherein R 8 is hydrogen or alkyl, and the nitrogen of —SO 2 N(R 4 )R 5 or —N(R 4 )SO 2 R 5 is N − ; or

R 4 and R 5 together with the intervening atom or atoms bound thereto form a heterocyclic or substituted heterocyclic group; or

R 5 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, amino, cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocyclic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, and acyl; or

R 4 and R 5 together with the intervening atom or atoms bound thereto form a heterocyclic or a substituted heterocyclic group;

R 6 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocyclic, carboxyl, carboxyl ester, aryl, substituted aryl, heteroaryl, substituted heteroaryl, acyl and M + , wherein M + is a counterion selected from the group consisting of K + , Na + , Li + or + N(R 8 ) 4 , wherein R 8 is hydrogen or alkyl, and the nitrogen of —SO 2 N(R 6 )R 7 or —N(R 6 )SO 2 R 7 is N − ; or

R 6 and R 7 together with the intervening atom or atoms bound thereto, form a heterocyclic or a substituted heterocyclic group; or

if W is alk 2 -SO 2 N(R 6 )R 7 , then R 6 and R 7 together with the nitrogen atom bound thereto optionally form —N═C(OR 9 ) 2 wherein each R 9 independently is an alkyl group; and

R 7 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, amino, cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocyclic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, carboxyl, carboxyl ester, and acyl;

provided that when X is hydrogen, ring A is not benzimidazolyl or indazolyl.

2. The method of claim 1 which is carried out in vitro.

3. The method of claim 1 which is carried out in vivo.

4. The method of claim 3 , wherein the compound is administered to a subject suffering from a T-cell mediated autoimmune disease.

5. The method of claim 4 in which the compound is administered in combination with, or adjunctively to, a compound that inhibits Syk kinase with an IC 50 in the range of at least 10 μM.

6. The method of claim 4 , wherein the subject is a transplant recipient suffering from or predisposed to an allograft transplant rejection.

7. The method of claim 6 , wherein the compound is administered to a tissue or an organ prior to transplanting the tissue or organ in the transplant recipient.

8. The method of claim 6 in which the rejection is acute rejection.

9. The method of claim 6 in which the rejection is chronic rejection.

10. The method of claim 6 in which the rejection is mediated by HVGR or GVHR.

11. The method of claim 6 in which the allograft transplant is selected from a kidney, a heart, a liver or a lung.

12. The method of claim 6 in which the compound is administered in combination with, or adjunctively to, another immunosuppressant.

13. The method of claim 12 in which the immunosuppressant is selected from cyclosporine, tacrolimus, sirolimus, an inhibitor of IMPDH, mycophenolate, mycophanolate mofetil, an anti-T-Cell antibody or OKT3.

14. The method of claim 3 , wherein the compound is administered to a subject suffering from or predisposed to develop a Type IV hypersensitivity reaction.

15. The method of claim 14 wherein the compound is administered prophylactically.

16. The method of claim 1 , wherein the method inhibits a signal transduction cascade in which JAK3 kinase plays a role.

17. The method of claim 4 , wherein the compound is selected from:

IV-5 N2-(3-Aminosulfonylmethylenephenyl)-5-fluoro-N4-[2-(2-N-morpholinoethylaminoacarbonyl)benzofuran-5-yl]-2,4-pyrimidinediamine;

IV-2 N2-[3-(Aminosulfonylmethylene)phenyl]-N4-[2,2-dimethyl-3-oxo-4methyl-pyrid[1,4]oxazin-7-yl]-5-fluoro-2,4-pyrimidinediamine;

IV-3 N2-(3-Aminosulfonylmethylphenyl)-5-fluoro-N4-[1-(propyn-3-yl)indol-5-yl]-2,4-pyrimidinediamine;

IV-4 N2-[3-(Aminosulfonylmethylene)phenyl]-N4-(3-cyanomethylene-1H-indol-5-yl)-5-5-fluoro-2,4-pyrimidinediamine;

IV-1 N2-[3-(Aminosulfonylmethylene)phenyl]-N4-[2,2-dimethyl-3-oxo-4H-pyrid[1,4]oxazin-7-yl]-5-fluoro-2,4-pyrimidinediamine;

III-3 N2-(2-Aminosulfonyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-N4-(2,2-dimethyl-3-oxo-4H-5-pyrid[1,4]oxazin-6-yl)-5-fluoro-2,4-pyrimidinediamine;

V-1 N2-(4-aminosulfonyl)phenyl-5-fluoro-N4-(2,2-dioxo-5-fluoro-1,3-dihydrobenzo[c]isothiazol-6-yl)-2,4-pyrimidinediamine;

V-2 N2-(3-aminosulfonyl)phenyl-5-fluoro-N4-(2,2-dioxo-5-fluoro-1,3-dihydrobenzo[c]isothiazol-6-yl)-2,4-pyrimidinediamine;

V-3 N2-(3-aminosulfonyl-4-methyl)phenyl-5-fluoro-N4-(2,2-dioxo-5-fluoro-1,3-dihydrobenzo[c]isothiazol-6-yl)-2,4-pyrimidinediamine;

V-4 N4-[2,2-dimethyl-3-oxo-4H-pyrid[1,4]oxazin-7-yl]-N2-[3,3-dioxo-1H-benzo[e][1,3,4]oxathiazin-7-yl]-5-fluoro-2,4-pyrimidinediamine;

V-5 N2-(3-Benzyl-cyclopropanesulfonamide-)-N4-(3,4-dihydroquinolin-1H-6-yl)-5-methyl-2,4-pyrimidinediamine; or

III-4 N2-(2-Aminosulfonyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-N4-(4-(prop-2-ynyloxy)phenyl)-5-fluoro-2,4-pyrimidinediamine.